Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 88Neoplasms 6HER2-positive Breast Cancer 5Triple Negative Breast Neoplasms 4Prostatic Neoplasms 4Ovarian Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Stomach Neoplasms 3Neoplasm Metastasis 3Multiple Myeloma 3Colorectal Neoplasms 3Urinary Bladder Neoplasms 2Rectal Neoplasms 2Pathologic Complete Response 2Pancreatic Neoplasms 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Locally Advanced Breast Cancer 2Inflammatory Breast Neoplasms 2Colonic Neoplasms 2Brain Neoplasms 2Biliary Tract Neoplasms 2Anatomic Stage I Breast Cancer AJCC v8 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Solid Cancers 1Salivary Gland Neoplasms 1Neuroendocrine Tumors 1Neuroblastoma 1

Interventions

pertuzumab 2Paclitaxel 2Carboplatin 2pegfilgrastim 1Trastuzumab 1Hydralazine 1Doxorubicin 1Docetaxel 1Cyclophosphamide 1Clinical Protocols 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Locally Advanced Breast Cancer × pertuzumab × Clear all
NCT03329378 2023-08-22

Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer

Icahn School of Medicine at Mount Sinai

Phase 2 Terminated
7 enrolled 10 charts
Breast

Locally Advanced Breast Cancer

NCT05749016 2023-03-01

Neoadjuvant Inetetamab Combined With Pertuzumab and Paclitaxel/Carboplatin for Breast Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Unknown
30 enrolled
Breast

Locally Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡